Epithalon (Epitalon) · Research brief

How Many Doses Per Vial of Epithalon? — Real Peptides

Real Peptides Research TeamEditorial

Updated April 7, 202610 min read

46 WORDS

Short answer

Key takeaways

A 10mg Epithalon vial yields 10 doses at 1mg per administration, or 20 doses at 0.5mg per administration. The peptide amount is fixed; dose per injection is researcher-defined.
Reconstitution volume determines concentration and injection volume, but does not change the total number of doses extractable from the vial.
Lyophilised Epithalon remains stable at −20°C for 24–36 months; once reconstituted, it must be refrigerated at 2–8°C and used within 28 days.
Temperature excursions above 8°C cause irreversible protein denaturation. Strict cold chain management is non-negotiable for peptide stability.
Most published Epithalon research protocols use 0.5mg to 1mg per administration, delivered subcutaneously in 10-day cycles.

How Many Doses Per Vial of Epithalon?

Researchers purchasing Epithalon for the first time consistently ask the same question: how many administrations can I extract from a single 10mg vial? The answer isn't printed on the label because it depends entirely on two variables you control. Reconstitution volume and target dose per injection. A 10mg vial reconstituted with 2mL bacteriostatic water yields 20 doses at 0.5mg each, or 10 doses at 1mg each. The peptide amount is fixed; the dose per administration is not.

Our team has guided hundreds of research protocols through peptide reconstitution. The yield calculation is simple arithmetic, but the preparation stage is where most contamination and potency failures occur. Not the injection itself.

How many doses are in a 10mg Epithalon vial?

A 10mg Epithalon vial contains 10,000 micrograms of lyophilised peptide. The number of doses extracted depends on your reconstitution volume and desired dose per administration. At 0.5mg per dose, a 10mg vial yields 20 administrations. At 1mg per dose, it yields 10 administrations. The peptide is stable in lyophilised form at −20°C before mixing. Once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days to prevent degradation.

Most published Epithalon research protocols use doses between 0.5mg and 1mg per administration, delivered subcutaneously. The peptide's mechanism involves stimulation of endogenous telomerase activity in somatic cells. A process that operates through epigenetic modification of the TERT gene promoter region rather than direct enzymatic activation. This is mechanistically distinct from exogenous telomerase delivery, which is why dose precision matters: underdosing fails to trigger sufficient transcriptional upregulation, while significant overdosing provides no additional benefit and wastes research material. The relationship between dose and telomerase expression follows a saturation curve, not a linear one.

Reconstitution Math: Converting Milligrams to Doses

The dose calculation requires three inputs: total peptide amount in the vial (milligrams), reconstitution volume (milliliters), and target dose per administration (milligrams). The formula is: (total peptide ÷ target dose per administration) = total number of doses. A 10mg vial at 1mg per dose yields 10 doses. At 0.5mg per dose, it yields 20 doses. At 2mg per dose, it yields 5 doses.

Reconstitution volume determines concentration, which then determines injection volume per dose. If you reconstitute 10mg Epithalon with 2mL bacteriostatic water, the resulting concentration is 5mg/mL. To extract a 1mg dose from a 5mg/mL solution, you draw 0.2mL (20 units on a 1mL insulin syringe). To extract a 0.5mg dose, you draw 0.1mL (10 units). The volume you inject changes, but the peptide mass per dose remains constant.

Researchers often ask whether using more or less reconstitution water changes the number of doses available. It doesn't. The peptide amount is fixed at the moment of lyophilisation. Adding 1mL vs 2mL water changes only the concentration and the injection volume required per dose, not the total number of administrations the vial can support. A 10mg vial always contains exactly 10mg of peptide regardless of how much water you add.

One critical preparation detail most protocols omit: when drawing bacteriostatic water into the syringe, inject it slowly down the side of the vial rather than directly onto the lyophilised powder. Direct impact can denature the peptide structure at the injection point, reducing bioavailability even if the solution appears clear. The goal is gentle dissolution, not rapid agitation. Swirl. Don't shake. And allow the vial to sit at room temperature for 2–3 minutes before refrigerating.

Storage and Stability: How Long Does Reconstituted Epithalon Last?

Lyophilised Epithalon stored at −20°C before reconstitution maintains potency for 24–36 months from the synthesis date. Once mixed with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Beyond that window, oxidative degradation and peptide bond hydrolysis reduce the active compound concentration unpredictably. Appearance remains clear, but potency declines.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth but does not prevent peptide degradation. The 28-day window reflects the stability limit of the peptide itself, not the sterility of the solution. Researchers using protocols that span more than four weeks should calculate dose requirements and reconstitute only the volume needed for that period, storing the remaining vials in lyophilised form.

Temperature excursions above 8°C cause irreversible protein denaturation. A vial left at room temperature for six hours may appear unchanged, but tertiary structure collapse has already occurred. Neither visual inspection nor home potency testing can detect this. The only reliable safeguard is strict cold chain adherence. Purpose-built peptide coolers like the FRIO wallet use evaporative cooling to maintain 2–8°C for 36–48 hours without ice or electricity, which matters for research teams working in field conditions or during transport.

We've reviewed storage protocols across hundreds of research settings. The single most common error is freezing reconstituted peptides. Freezing causes ice crystal formation that physically disrupts the peptide structure. Once mixed with water, Epithalon must remain refrigerated, never frozen. The lyophilised powder tolerates freezing; the reconstituted solution does not.

Epithalon Dose Comparison: Research Protocol Standards

Dose per Administration	Total Peptide Used per 10-Day Cycle	Number of Doses from 10mg Vial	Injection Volume (if reconstituted with 2mL)	Research Context
0.5mg	5mg	20 doses	0.1mL (10 units)	Standard exploratory dosing for initial telomerase response assessment
1mg	10mg	10 doses	0.2mL (20 units)	Most commonly cited dose in published rodent longevity studies
2mg	20mg	5 doses	0.4mL (40 units)	Higher-intensity protocols. Requires two 10mg vials per 10-day cycle

What If: Epithalon Dosing Scenarios

What If I Accidentally Left My Reconstituted Epithalon at Room Temperature Overnight?

Discard the vial. Even if the solution appears clear and uncontaminated, tertiary protein structure collapse begins within 4–6 hours above 8°C. The peptide may retain partial activity, but potency is unpredictable. Continuing the protocol with degraded material introduces uncontrolled variables that invalidate results. Lyophilised backup vials stored at −20°C are unaffected and can be reconstituted to replace the compromised solution.

What If I Want to Extract More Than 20 Doses from a 10mg Vial?

You can't. The peptide amount is fixed at synthesis. Reducing the dose per administration below 0.5mg increases the number of injections extractable, but sub-threshold dosing may fail to trigger measurable telomerase upregulation. Published Epithalon research consistently uses doses between 0.5mg and 2mg per administration; doses below 0.5mg appear in exploratory toxicity studies but not in efficacy trials. If your protocol requires more than 20 administrations, order additional vials rather than diluting below effective dose thresholds.

What If I Reconstituted with 1mL Instead of 2mL — Does That Change the Dose Count?

No. A 10mg vial reconstituted with 1mL yields a 10mg/mL solution; reconstituted with 2mL, it yields a 5mg/mL solution. The concentration changes, but the total peptide mass remains 10mg. You'll draw a smaller injection volume from the more concentrated solution to deliver the same dose. 0.1mL from a 10mg/mL solution delivers 1mg, while 0.2mL from a 5mg/mL solution also delivers 1mg. The number of doses extractable is determined by total peptide ÷ target dose, not by reconstitution volume.

The Unvarnished Truth About Epithalon Vial Yield

Here's the honest answer: the question 'how many doses per vial' assumes the peptide inside matches the label claim. It doesn't always. Third-party purity testing of research peptides consistently reveals ±10–20% variance from stated concentration. A vial labelled 10mg may contain 8.5mg or 11.2mg depending on synthesis batch and lyophilisation efficiency. This variance matters because your dose calculation assumes the label is accurate. If the actual peptide content is 8mg and you calculate doses assuming 10mg, every administration is underdosed by 20%.

Reputable suppliers provide Certificates of Analysis with HPLC purity verification and exact peptide content per vial. Generic suppliers selling peptides without CoAs often list peptide amounts as nominal rather than verified. The label states what was synthesised, not what survived lyophilisation and packaging. For research requiring dose precision, peptide sourcing matters as much as reconstitution technique. Explore high-purity research peptides with verified peptide content per vial. Batch-to-batch consistency isn't optional when protocols depend on it.

Injection Volume and Syringe Selection for Epithalon Administration

Most Epithalon protocols use subcutaneous injection volumes between 0.1mL and 0.4mL. Standard 1mL insulin syringes graduated in 0.01mL increments (100-unit syringes) provide sufficient precision for research dosing. Drawing volumes smaller than 0.05mL increases measurement error. If your reconstitution produces a concentration requiring injection volumes below 0.05mL, use less reconstitution water to increase concentration and injection volume proportionally.

Syringe dead space. The residual volume trapped in the needle hub and tip after injection. Averages 0.02–0.04mL depending on needle gauge. This represents 2–4% of a 1mL syringe's total volume, which compounds across multiple draws from the same vial. For high-precision dosing, low dead space syringes reduce this loss, but standard insulin syringes are adequate for most research applications where ±5% dose variance is acceptable.

Our team's experience with peptide reconstitution shows that injection volume precision matters less than reconstitution sterility. A 5% dose variance due to syringe dead space is negligible compared to the potency loss from introducing contaminants during vial access. Every needle puncture through the vial stopper creates a contamination risk. Minimising the number of draws per vial by using appropriate concentration reduces this exposure.

The standard protocol at Real Peptides reconstitutes 10mg Epithalon with 2mL bacteriostatic water, yielding a 5mg/mL solution. This concentration allows 1mg doses with 0.2mL injections and 0.5mg doses with 0.1mL injections. Both volumes within the accurate measurement range of standard insulin syringes. Researchers requiring doses outside this range should adjust reconstitution volume rather than attempting to measure injection volumes below 0.05mL or above 0.5mL per administration.

One critical insight most guides omit: inject air into the vial before drawing peptide solution. As you extract liquid, negative pressure builds inside the sealed vial, which pulls contaminants back through the needle on subsequent draws. Injecting 0.1–0.2mL of air before each draw equalises pressure and prevents backflow contamination. A step that takes two seconds but meaningfully extends vial sterility across multiple uses.

Epithalon's mechanism involves stimulation of the TERT gene promoter region through a yet-uncharacterised signalling pathway. Current evidence suggests it operates through epigenetic modification rather than direct protein-protein interaction. This means dose-response curves are nonlinear: doubling the dose does not double the telomerase expression. Researchers designing protocols should reference published dose ranges (0.5mg–2mg per administration in rodent models) rather than extrapolating from unrelated peptide classes.

For research teams requiring consistent batch-to-batch performance, sourcing matters. Real Peptides synthesises every peptide through small-batch production with exact amino-acid sequencing, guaranteeing purity and peptide content verification through third-party HPLC. Generic suppliers often use large-batch synthesis with statistical sampling. Individual vials may vary significantly from the stated concentration even if the batch average is accurate. When protocol validity depends on dose precision, peptide sourcing is a research decision, not a procurement decision.

The 28-day stability window for reconstituted Epithalon reflects oxidative degradation kinetics under refrigerated conditions. Peptides containing methionine or cysteine residues are particularly vulnerable to oxidation. Epithalon's tetrapeptide sequence (Ala-Glu-Asp-Gly) lacks these residues, but terminal amine oxidation still occurs over time. Antioxidant additives like ascorbic acid can extend stability slightly, but introduce variables that may interfere with research outcomes. The conservative approach is strict adherence to the 28-day window rather than attempting to extend it through additives.

Most Epithalon research uses 10-day administration cycles with 10–20 day rest periods between cycles. A 10mg vial at 1mg per dose supports one complete 10-day cycle; at 0.5mg per dose, it supports two cycles. Researchers planning multi-cycle protocols should calculate total peptide requirements before ordering. Running out mid-cycle forces either premature termination or switching to a new batch mid-protocol, both of which introduce confounding variables.

Our assessment after working with research teams across hundreds of peptide protocols: the most common yield miscalculation occurs when researchers confuse peptide mass with peptide purity. A vial labelled '10mg at 98% purity' contains 9.8mg of active peptide and 0.2mg of synthesis byproducts or residual salts. The dose calculation should use 9.8mg, not 10mg. A 2% error that compounds across multi-week protocols. Certificates of Analysis list both total mass and purity percentage; use the product of the two for accurate dose calculations.

References

Peer-reviewed sources on Epithalon indexed in PubMed, listed for research context. Real Peptides supplies Epithalon for laboratory research use only.

Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences, 2025. PMID 40141333. doi:10.3390/ijms26062691
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025. PMID 40908429. doi:10.1007/s10522-025-10315-x
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem cell reviews and reports, 2025. PMID 40493162. doi:10.1007/s12015-025-10911-x
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 2022. PMID 35413689. doi:10.18632/aging.204007
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland), 2020. PMID 32019204. doi:10.3390/molecules25030609
Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bulletin of experimental biology and medicine, 2013. PMID 23658898. doi:10.1007/s10517-013-2029-0
Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of experimental biology and medicine, 2008. PMID 19110597. doi:10.1007/s10517-008-0121-7
Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa. International journal of molecular medicine, 2003. PMID 12964022

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

A 10mg Epithalon vial yields 10 doses at 1mg per administration or 20 doses at 0.5mg per administration. The total peptide amount is fixed at synthesis — reconstitution volume changes concentration and injection volume but does not change the number of doses extractable. Most published research protocols use doses between 0.5mg and 1mg per administration delivered subcutaneously in 10-day cycles.

Sterile water lacks the preservative (0.9% benzyl alcohol) that inhibits bacterial growth in multi-dose vials. If you plan to extract only a single dose immediately after reconstitution, sterile water is acceptable — but any remaining solution must be discarded within 24 hours. Bacteriostatic water extends vial stability to 28 days under refrigeration, which is essential for protocols requiring multiple draws from the same vial.

Cost per dose depends on vial price and doses extracted. A 10mg vial priced at $80 yields 20 doses at 0.5mg each ($4 per dose) or 10 doses at 1mg each ($8 per dose). Research-grade Epithalon from verified suppliers with Certificates of Analysis typically costs $70–$120 per 10mg vial depending on batch size and purity verification. Generic peptides without third-party testing may be cheaper but introduce dose variability that compromises protocol validity.

Freezing reconstituted peptides causes ice crystal formation that physically disrupts the peptide structure, rendering the solution unusable. Lyophilised Epithalon tolerates freezing at −20°C before reconstitution, but once mixed with bacteriostatic water, it must remain refrigerated at 2–8°C — never frozen. If a reconstituted vial is accidentally frozen, discard it and reconstitute a fresh vial from lyophilised stock.

Epithalon and Epitalon are the same compound — the name variance reflects transliteration differences from Cyrillic script. Dosing protocols are identical. [Thymalin](https://www.realpeptides.co/products/thymalin/), a thymic peptide bioregulator, operates through a different mechanism (thymic immune modulation rather than telomerase activation) and uses different dose ranges — typically 5–10mg per administration in research models. The peptides are not interchangeable; protocols must be designed around each compound’s specific mechanism of action.

No — once the vial seal is punctured, sterility cannot be guaranteed even if peptide remains inside. The standard protocol is to reconstitute the entire vial contents at once and extract doses as needed over the 28-day stability window. Partial reconstitution introduces contamination risk that outweighs any theoretical shelf-life extension. If your protocol requires fewer than 10 doses over several months, order smaller vials (5mg or 2mg) rather than attempting partial reconstitution of larger vials.

Subcutaneous Epithalon is typically administered in the abdominal region 2–3 inches lateral to the navel, rotating injection sites to prevent lipohypertrophy. Pinch the skin to create a fold, insert the needle at a 45-degree angle, and inject slowly over 3–5 seconds. Most research protocols use 29-gauge or 30-gauge needles with 0.5-inch length, which penetrate subcutaneous tissue without reaching muscle. Injection technique errors (too shallow, too fast, failure to rotate sites) cause localised irritation but do not affect peptide bioavailability meaningfully.

Lyophilised Epithalon tolerates ambient temperature shipping for 3–5 days without significant degradation — the peptide is stable at room temperature in its freeze-dried form. Temperature-sensitive shipping with ice packs is unnecessary for lyophilised vials but is required for pre-reconstituted solutions. Visual inspection cannot detect degradation — a clear solution may have reduced potency if exposed to heat. Reputable suppliers include temperature monitors or guarantee cold chain compliance; if a vial arrives warm and the supplier cannot verify shipping conditions, request a replacement.

A standard Epithalon research protocol involves 10 consecutive days of administration (one dose per day) followed by a 10–20 day rest period before the next cycle. At 1mg per dose, a 10mg vial supports one complete 10-day cycle. At 0.5mg per dose, it supports two cycles. The rest period allows endogenous telomerase expression to return to baseline before re-stimulation — continuous dosing without breaks has not been studied extensively in longevity research and is not standard protocol.

Request a Certificate of Analysis showing HPLC purity (should be ≥98%), exact peptide content per vial (not just nominal amount), synthesis method (solid-phase peptide synthesis is standard), and batch testing date. Ask whether the peptide content listed reflects pre-lyophilisation or post-lyophilisation mass — some suppliers list the peptide amount before freeze-drying, which overstates the actual dose per vial. Verify whether bacteriostatic water is included or sold separately. Suppliers who cannot provide third-party verified CoAs should not be used for dose-sensitive research protocols.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA